Poster 528 Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Safety and Analgesic Efficacy of MNK-795 Oxycodone/Acetaminophen Extended-Release Tablets in an Acute Pain Model

PM&R ◽  
2014 ◽  
Vol 6 (9) ◽  
pp. S371-S372
Author(s):  
Neil Singla ◽  
Thomas Barrett ◽  
Lisa Sisk ◽  
Kenneth Kostenbader ◽  
Jim Young
Keyword(s):  
Acute Pain ◽  
Extended Release ◽  
Analgesic Efficacy ◽  
Open Label ◽  
Phase 3 ◽  
Double Blind ◽  
Pain Model ◽  
Double Blind Placebo ◽  
Open Label Extension

Safety and efficacy of incobotulinumtoxinA for the treatment of upper facial lines: A randomized, double-blind, placebo-controlled, phase 3 study with open-label extension

Toxicon ◽  
2018 ◽  
Vol 156 ◽  
pp. S110
Author(s):  
Patrick Trevidic ◽  
Simon A. Connolly ◽  
Bernard Biwer ◽  
Petra Weissenberger ◽  
Philippe Kestemont ◽  
...  
Keyword(s):  
Open Label ◽  
Phase 3 ◽  
Double Blind ◽  
Safety And Efficacy ◽  
Double Blind Placebo ◽  
Open Label Extension

scholarly journals Eculizumab monotherapy for NMOSD: Data from PREVENT and its open-label extension

2021 ◽  
pp. 135245852110382
Author(s):  
Sean J Pittock ◽  
Kazuo Fujihara ◽  
Jacqueline Palace ◽  
Achim Berthele ◽  
Ho Jin Kim ◽  
...  
Keyword(s):  
Relapse Prevention ◽  
Interim Analysis ◽  
Time To Event ◽  
Open Label ◽  
Phase 3 ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Kaplan Meier ◽  
Open Label Extension

During PREVENT (a phase 3, randomized, double-blind, placebo-controlled, time-to-event study) and its open-label extension (interim analysis), 33 adults with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG + NMOSD) received eculizumab monotherapy for a median of 2.8 years (range, 14 weeks–5.2 years). At 192 weeks (~4 years), 96% of these patients were free from adjudicated relapses (Kaplan–Meier analysis; 95% confidence interval, 75.7–99.4). During PREVENT, 95% (20/21) of patients receiving eculizumab monotherapy had no disability worsening. Eculizumab monotherapy provides effective long-term relapse prevention, relieving the chronic immunosuppression burden in patients with AQP4-IgG + NMOSD. ClinicalTrials.gov; PREVENT: NCT01892345; open-label extension: NCT02003144.

Sign in / Sign up

Export Citation Format

Share Document